DuoHexaBody-CD37®, a novel biparatopic CD37 antibody with enhanced Fc-mediated hexamerization as a potential therapy for B-cell malignancies
Simone C. Oostindie(Leiden University Medical Center), Esther C.W. Breij(Genmab (Netherlands)), Martine E.D. Chamuleau(Hovon), Frank J. Beurskens(Genmab (Netherlands)), Juliette van den Noort(Genmab (Netherlands)), Paul W.H.I. Parren(Leiden University Medical Center), Hilma J. van der Horst(Amsterdam University Medical Centers), Berris van Kessel(Genmab (Netherlands)), Kristin Strumane(Genmab (Netherlands)), Laurens P. Kil(Genmab (Netherlands)), Janine Schuurman(Genmab (Netherlands)), Marije B. Overdijk(Genmab (Netherlands)), Margaret A. Lindorfer(University of Virginia), Tuna Mutis(Amsterdam University Medical Centers), Edward N. van den Brink(Genmab (Netherlands)), Jeroen H. N. van den Brakel(Genmab (Netherlands)), Hendrik J. Rademaker(Genmab (Netherlands)), Ronald P. Taylor(University of Virginia)
Cited by 70
Related Papers
Daratumumab, a Novel Therapeutic Human CD38 Monoclonal Antibody, Induces Killing of Multiple Myeloma and Other Hematological Tumors
|The Journal of Immunology|2010|1k
Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 study
|The Lancet|2021|337
Dual Mode of Action of a Human Anti-Epidermal Growth Factor Receptor Monoclonal Antibody for Cancer Therapy
|The Journal of Immunology|2004|149